Baxter International Company Profile (NYSE:BAX)

About Baxter International

Baxter International logoBaxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: BAX
  • CUSIP: 07181310
Key Metrics:
  • Previous Close: $49.42
  • 50 Day Moving Average: $46.48
  • 200 Day Moving Average: $46.78
  • 52-Week Range: $36.67 - $50.16
  • Trailing P/E Ratio: 5.52
  • Foreward P/E Ratio: 20.30
  • P/E Growth: 1.62
  • Market Cap: $27.05B
  • Outstanding Shares: 543,919,000
  • Beta: 0.77
  • Net Margins: 48.85%
  • Return on Equity: 12.35%
  • Return on Assets: 6.58%
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 2.53%
  • Quick Ratio: 1.93%
Additional Links:
Companies Related to Baxter International:

Analyst Ratings

Consensus Ratings for Baxter International (NYSE:BAX) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $52.19 (4.94% upside)

Analysts' Ratings History for Baxter International (NYSE:BAX)
DateFirmActionRatingPrice TargetDetails
2/2/2017Barclays PLCReiterated RatingOverweight$57.00 -> $60.00View Rating Details
2/1/2017Evercore ISIBoost Price TargetBuy$50.00 -> $51.50View Rating Details
10/26/2016RBC Capital MarketsReiterated RatingSector Perform$50.00 -> $55.00View Rating Details
10/26/2016Royal Bank Of CanadaBoost Price TargetSector Perform$50.00 -> $55.00View Rating Details
10/13/2016Wells Fargo & CompanyInitiated CoverageOutperformView Rating Details
8/15/2016ArgusReiterated RatingHoldView Rating Details
7/27/2016J P Morgan Chase & CoBoost Price TargetNeutral$45.00 -> $48.00View Rating Details
7/6/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyView Rating Details
6/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$60.00View Rating Details
5/17/2016Leerink SwannUpgradeMarket Perform -> OutperformView Rating Details
5/10/2016Credit Suisse GroupReiterated RatingHoldView Rating Details
5/10/2016BMO Capital MarketsReiterated RatingHold$43.00View Rating Details
5/8/2016Morgan StanleyReiterated RatingSellView Rating Details
10/28/2015Cowen and CompanyLower Price Target$74.00 -> $38.00View Rating Details
7/31/2015S&P Equity ResearchDowngradeHold$42.00View Rating Details
7/13/2015Deutsche Bank AGReiterated RatingHold$66.00 -> $37.00View Rating Details
7/2/2015Bank of America CorpDowngradeBuy -> NeutralView Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Baxter International (NYSE:BAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2017Q416$0.52$0.57$2.65 billion$2.65 billionViewListenView Earnings Details
10/25/2016Q316$0.45$0.56$2.67 billion$2.56 billionViewListenView Earnings Details
7/26/2016Q216$0.40$0.46$2.51 billion$2.60 billionViewListenView Earnings Details
4/26/2016Q116$0.29$0.36$2.35 billion$2.40 billionViewListenView Earnings Details
2/2/2016Q415$0.32$0.43$2.55 billion$2.60 billionViewListenView Earnings Details
10/27/2015Q315$0.29$0.41$2.46 billion$2.49 billionViewListenView Earnings Details
7/29/2015Q215$0.94$1.00$2.40 billion$3.90 billionViewListenView Earnings Details
4/23/2015Q115$0.88$1.00$3.70 billion$3.76 billionViewListenView Earnings Details
1/29/2015Q414$1.32$1.34$4.37 billion$4.47 billionViewListenView Earnings Details
10/16/2014Q314$1.30$1.31$4.21 billion$4.20 billionViewListenView Earnings Details
7/17/2014Q214$1.22$1.26$4.12 billion$4.30 billionViewListenView Earnings Details
4/17/2014Q114$1.09$1.19$3.88 billion$3.95 billionViewListenView Earnings Details
1/23/2014Q413$1.25$1.26$4.25 billion$4.40 billionViewListenView Earnings Details
10/17/2013Q313$1.19$1.19$3.82 billion$3.80 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.13$1.16$3.70 billion$3.67 billionViewListenView Earnings Details
4/18/2013Q1 2013$1.04$1.05$3.49 billion$3.45 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.26$1.26$3.72 billion$3.75 billionViewListenView Earnings Details
10/18/2012$1.14$1.14ViewN/AView Earnings Details
7/19/2012$1.11$1.12ViewN/AView Earnings Details
4/19/2012$1.00$1.01ViewN/AView Earnings Details
1/26/2012$1.17$1.17ViewN/AView Earnings Details
10/20/2011$1.08$1.09ViewN/AView Earnings Details
7/21/2011$1.02$1.07ViewN/AView Earnings Details
4/21/2011$0.93$0.98ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Baxter International (NYSE:BAX)
Current Year EPS Consensus Estimate: $2.17 EPS
Next Year EPS Consensus Estimate: $2.45 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.28$0.29$0.29
Q2 20163$0.36$0.39$0.38
Q3 20162$0.44$0.44$0.44
Q4 20162$0.51$0.51$0.51
Q1 20172$0.50$0.51$0.51
Q2 20172$0.47$0.49$0.48
Q3 20172$0.57$0.58$0.58
Q4 20172$0.58$0.61$0.60
Q1 20182$0.53$0.55$0.54
Q2 20182$0.54$0.57$0.56
Q3 20182$0.62$0.64$0.63
Q4 20182$0.64$0.70$0.67
(Data provided by Zacks Investment Research)


Current Dividend Information for Baxter International (NYSE:BAX)
Annual Dividend:$0.52
Dividend Yield:1.05%
Dividend Growth:-36.10% (3 Year Average)
Payout Ratio:5.78% (Based on Trailing 12 Months of Earnings)
23.96% (Based on Current Year Consensus EPS Estimate)
21.22% (Based on Next Year Consensus EPS Estimate)

Dividend History for Baxter International (NYSE:BAX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Baxter International (NYSE:BAX)
Insider Ownership Percentage: 1.08%
Institutional Ownership Percentage: 83.20%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/8/2017John D ForsythDirectorSell4,280$48.35$206,938.00View SEC Filing  
5/23/2016Jose E AlmeidaCEOBuy11,691$42.75$499,790.25View SEC Filing  
5/2/2016John D ForsythDirectorSell1,887$44.38$83,745.06View SEC Filing  
4/4/2016John D ForsythDirectorSell1,887$41.75$78,782.25View SEC Filing  
3/14/2016James R Gavin IIIDirectorSell5,660$40.34$228,324.40View SEC Filing  
2/17/2016Peter S. HellmanDirectorSell5,660$38.35$217,061.00View SEC Filing  
2/11/2016Kornelis J. StormDirectorSell5,660$35.98$203,646.80View SEC Filing  
5/22/2015Carole J ShapazianDirectorSell1,533$67.68$103,753.44View SEC Filing  
4/27/2015James R Gavin IIIDirectorSell4,830$71.06$343,219.80View SEC Filing  
7/25/2014Carole J ShapazianDirectorSell1,645$76.98$126,632.10View SEC Filing  
7/24/2014Thomas T StallkampDirectorSell8,300$76.82$637,606.00View SEC Filing  
7/9/2014Ludwig HantsonVPSell24,693$76.00$1,876,668.00View SEC Filing  
5/2/2014Carole ShapazianDirectorSell5,680$75.28$427,590.40View SEC Filing  
4/23/2014Kees StormDirectorSell5,760$72.45$417,312.00View SEC Filing  
4/21/2014Blake DevittDirectorSell4,334$73.12$316,902.08View SEC Filing  
3/27/2014Sebastian BufalinoVPSell21,600$75.10$1,622,160.00View SEC Filing  
9/12/2013Carole ShapazianDirectorSell1,941$71.58$138,936.78View SEC Filing  
8/1/2013Robert L Parkinson JrCEOSell725,750$73.33$53,219,247.50View SEC Filing  
7/26/2013David P ScharfVPSell55,438$73.79$4,090,770.02View SEC Filing  
7/25/2013James R Gavin IIIDirectorSell5,760$72.82$419,443.20View SEC Filing  
7/24/2013Carole J ShapazianDirectorSell4,320$73.58$317,865.60View SEC Filing  
7/22/2013Robert J HombachCFOSell47,452$73.95$3,509,075.40View SEC Filing  
7/16/2013Phillip L BatchelorVPSell5,850$73.00$427,050.00View SEC Filing  
5/22/2013Blake E DevittDirectorSell1,000$72.34$72,340.00View SEC Filing  
5/20/2013Sebastian J BufalinoVPSell24,000$73.75$1,770,000.00View SEC Filing  
5/17/2013Robert M DavisVPSell130,800$73.00$9,548,400.00View SEC Filing  
9/13/2012Michael J BaughmanVPSell11,500$61.00$701,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Baxter International (NYSE:BAX)
DateHeadline logoBaxter International Inc. - Strategy, SWOT and Corporate Finance Report - New Market Research Report (NYSE:BAX) - February 20 at 9:58 AM
News IconImpact Score Of Baxter International Inc. (NYSE:BAX) At 100 - Stock Observer (NYSE:BAX) - February 19 at 10:15 AM logoBaxter International : to Present at the 38th Annual Raymond James Institutional Investor Conference (NYSE:BAX) - February 18 at 3:43 PM
News IconBuy or Sell? Average Brokerage Ratings on Baxter International Inc ... - StockNewsJournal (NYSE:BAX) - February 18 at 7:59 AM
News IconSorting Out the Technicals on Shares of Baxter International Inc. (BAX) - Midway Monitor (NYSE:BAX) - February 17 at 3:31 PM
News IconLookout for Price Target? Baxter International Inc. (BAX), Archer-Daniels-Midland Company (ADM) - StockNewsJournal (NYSE:BAX) - February 17 at 10:35 AM
News IconDividend Growth of Baxter International Inc.(BAX) - Highland Mirror (NYSE:BAX) - February 17 at 10:35 AM logoBaxter Debuts Enteral Nutrition ENFit® Syringe and Accessory Line ... - Business Wire (press release) (NYSE:BAX) - February 16 at 3:51 PM logoBaxter International Inc (BAX) Stock Looks Good to Dan Loeb - (NYSE:BAX) - February 16 at 3:51 PM logoBaxter Debuts Enteral Nutrition ENFit® Syringe and Accessory Line During Clinical Nutrition Week 2017 (NYSE:BAX) - February 16 at 8:44 AM logoBaxter International Inc (BAX) Stock Looks Good to Dan Loeb (NYSE:BAX) - February 15 at 11:51 AM
News IconAnalysts Near-Term outlook: Consolidated Edison, Inc. (ED), Baxter International Inc. (BAX) - The USA Commerce (NYSE:BAX) - February 14 at 3:26 PM
News IconWhy to Keeping Eye on WestRock Company (WRK), Baxter International Inc. (BAX)? - StockNewsJournal (NYSE:BAX) - February 14 at 3:26 PM logoInsider Trading Activity Baxter International Inc. (NYSE:BAX) – Director Sold 4,280 shares of Stock (NYSE:BAX) - February 12 at 3:51 PM
News IconAnchor Capital Advisors Cuts Position in Baxter International Inc (BAX) by $51647720 (NYSE:BAX) - February 11 at 2:23 AM
News IconBaxter International Inc. (NYSE:BAX) PT Suggests Stock Is Worth Around $52.88 (NYSE:BAX) - February 11 at 2:23 AM logo[$$] How to Invest With Ackman and Loeb (NYSE:BAX) - February 11 at 2:23 AM logoPerrigo Company Becomes #241 Most Shorted S&P 500 Component, Replacing Baxter International (NYSE:BAX) - February 10 at 9:22 PM
News IconNoesis Capital Mangement Corp Cuts Position in Baxter International Inc (BAX) by $4556041 - Highland Mirror (NYSE:BAX) - February 10 at 4:22 PM
News IconMedTech Innovator Announces Baxter as Newest Industry Partner (NYSE:BAX) - February 10 at 2:03 AM
News IconInspirion Wealth Advisors Boosts Position by $1691223 in Baxter International Inc (BAX) (NYSE:BAX) - February 10 at 2:03 AM logoBaxter to Present at the 38th Annual Raymond James Institutional Investor Conference - Business Wire (press release) (NYSE:BAX) - February 9 at 9:02 PM
News IconBaxter International Inc. (NYSE:BAX) News Impact Score At 42 ... - Stock Observer (NYSE:BAX) - February 9 at 9:02 PM
News IconEarnings Clues on ServiceNow, Inc. (NOW), Baxter International Inc ... - StockNewsJournal (NYSE:BAX) - February 9 at 9:02 PM logoBaxter to Present at the 38th Annual Raymond James Institutional Investor Conference (NYSE:BAX) - February 9 at 9:02 PM
News IconDirector of Baxter International Inc (NYSE:BAX), Shapazian Carole J, sells 4,280 shares worth $206,424 (NYSE:BAX) - February 8 at 8:58 PM logoBaxter to Present at the 37th Annual Cowen and Company Healthcare Conference (NYSE:BAX) - February 8 at 8:58 PM
News IconRevenue Approximations Analysis: Molson Coors Brewing ... - StockNewsJournal (NYSE:BAX) - February 8 at 3:57 PM logoBaxter Appoints Dr. Stephen Oesterle to Its Board (NYSE:BAX) - February 8 at 3:57 PM logoBAXTER INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial State (NYSE:BAX) - February 8 at 3:57 PM logoBaxter International, Inc. :BAX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017 (NYSE:BAX) - February 6 at 3:50 PM logoETFs with exposure to Baxter International, Inc. : February 6, 2017 (NYSE:BAX) - February 6 at 3:50 PM
News IconWhat Analysts Report Shows About Baxter International Inc. (NYSE:BAX)? - Transcript Daily (NYSE:BAX) - February 4 at 8:58 PM
News IconImpact Score Of Baxter International Inc. (NYSE:BAX) At 72 - Stock Observer (NYSE:BAX) - February 4 at 3:52 PM
News IconBaxter International Inc. (NYSE:BAX) from Medical Instruments & Supplies – Todays Top Gains (NYSE:BAX) - February 4 at 2:01 AM logoBaxter International, Inc. :BAX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 3, 2017 (NYSE:BAX) - February 4 at 2:01 AM logoBaxter International, Inc. :BAX-US: Earnings Analysis: 2016 By the Numbers : February 3, 2017 (NYSE:BAX) - February 4 at 2:01 AM logoBaxter International Inc. (NYSE:BAX) EPS Projection At $0.73 - (NYSE:BAX) - February 3 at 8:59 PM logoNotable Movers Xerox Corp (NYSE:XRX), Baxter International Inc ... - Wall Street 24 (NYSE:BAX) - February 3 at 3:56 PM
News IconAnalyst's Predictions on Las Vegas Sands Corp. (LVS), Baxter International Inc. (BAX) - StockNewsJournal (NYSE:BAX) - February 3 at 3:56 PM logoBaxter International profit climbs 19% (NYSE:BAX) - February 2 at 8:58 PM
News IconAs Baxter International INC (BAX) Market Value Rose, Shareholder Vaughan David Investments INC Has Lowered Holding by $4.71 Million (NYSE:BAX) - February 2 at 3:57 PM logoBaxter International Inc Bumps Its Bottom Line (NYSE:BAX) - February 2 at 3:57 PM
News IconWheatland Advisors Inc Cuts Position in Baxter International Inc (BAX) by $2191197 (NYSE:BAX) - February 1 at 9:01 PM logoBaxter International Inc. (NYSE:BAX) Files An 8-K Results of Operations and Financial Condition (NYSE:BAX) - February 1 at 9:01 PM
News IconOakworth Capital Boosts Position by $935009 in Baxter International Inc (BAX) (NYSE:BAX) - February 1 at 9:01 PM
News IconThe Baxter International Inc. (BAX) Stake Held by Wellington Shields & Co. LLC (NYSE:BAX) - February 1 at 9:01 PM logoBRIEF-Baxter International reports Q4 earnings per share of $0.44 (NYSE:BAX) - February 1 at 9:01 PM logoBaxter International Inc 2016 Q4 - Results - Earnings Call Slides (NYSE:BAX) - February 1 at 9:01 PM
News IconBaxter International Inc. Reveals 32% Advance In Q4 Profit (NYSE:BAX) - February 1 at 9:01 PM


What is Baxter International's stock symbol?

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International announced a quarterly dividend on Tuesday, November 8th. Investors of record on Friday, December 2nd will be given a dividend of $0.13 per share on Tuesday, January 3rd. This represents a $0.52 dividend on an annualized basis and a yield of 1.05%. The ex-dividend date is Wednesday, November 30th.

Where is Baxter International's stock going? Where will Baxter International's stock price be in 2017?

13 brokers have issued 12-month target prices for Baxter International's shares. Their forecasts range from $43.00 to $60.00. On average, they anticipate Baxter International's stock price to reach $52.19 in the next twelve months.

When will Baxter International announce their earnings?

Baxter International is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.

What are analysts saying about Baxter International stock?

Here are some recent quotes from research analysts about Baxter International stock:

  • Evercore ISI analysts commented, "BAX reported a solid finish to the year, beating consensus EPS estimates by double digits and initiating above ST EPS guidance. There were several highlights in the 4Q print, both on the topline and operating metrics that made us incrementally more positive on our 'turnaround + long term EPS power underappreciated by Street' thesis. From a revenue perspective, Renal came in above, and management highlighted continued strong adoption of AMIA PD with patient volumes doubling past few Qs (AMIA will be a key long term driver, and these trends bode well). While management guided to 3-4% growth for Renal in FY17, we think the low end of the guidance seems conservative given strength in underlying business + AMIA uptake. Within Fluid Systems, yet another strong high single digit showing highlighted the strength of Sigma Spectrum pump uptake. We found it interesting that guidance assumes 'flattening of Sigma pump in 2017', which we think is a conservative assumption (competitor BDX still expects pump share gains in FY17). Overall, the constant currency growth of ~2% seems conservative, with potential upside in the event of lack of competitive entrants for cyclo business. On the margin front, while FY17 OM of ~15% seems optically below the ~15.7% seen in 2H'16 levels (but equates to an expansion of ~150 bps over FY16), we note that it contemplates about 150 bps of headwinds related to cyclo competition, Fx & TSA rolling off. As such, the ~15% OM guidance seems prudent to us, with possible upside tied to lack of competitive cyclo entrants. Finally, the EPS guide of $2.10-2.18 does not assume any share repo and no contribution from Claris. In light of the impressive free cash increase (FY16 FCF came in 80% above original guidance; FY17 guide of >$1 Bn) and ~$1 Bn of repatriation, we see upside potential to EPS upside tied to capital deployment. All in, this was a solid print, and current levels provide a good entry point for long term holders (we note BAX repurchased $250 MM worth of shares at an avg. of $47.50 in 4Q, which is around current trading levels)." (2/1/2017)
  • According to Zacks Investment Research, "Over the past one year Baxter has outperformed the broader industry in terms of price performance. Additionally, a favorable estimate revision trend for the current year instills our confidence on the stock. Of the major concerns, lower sales in the cyclophosphamide platform are expected to negatively impact the company’s top line. Additionally, foreign currency volatility, intense competition in the medical products segment and lackluster hospital spending are the major concerns for the near-term. Baxter depends on the European Union for about a third of its sales. This is a cause for concern, given the sluggish macro-environment, a glum outlook for hospital spending and tightening of reimbursement. However, on the positive side, management provided positive guidance for the rest of 2016. Both sales and earnings are forecasted to improve driven by the company’s robust portfolio and growing addressable market." (1/17/2017)

Who owns Baxter International stock?

Baxter International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (0.00%), Janus Capital Management LLC (0.63%), Tweedy Browne Co. LLC (0.00%), Russell Investments Group Ltd. (0.34%), Bessemer Group Inc. (0.00%) and New York State Teachers Retirement System (0.17%). Company insiders that own Baxter International stock include Carole J Shapazian, James R Gavin III, John D Forsyth, Jose E Almeida, Kornelis J Storm and Peter S Hellman.

Who sold Baxter International stock? Who is selling Baxter International stock?

Baxter International's stock was sold by a variety of institutional investors in the last quarter, including BP PLC, Teachers Retirement System of The State of Kentucky, Fred Alger Management Inc., Tweedy Browne Co. LLC, Metropolitan Life Insurance Co. NY, Barings LLC, Harfst & Associates Inc. and Tredje AP fonden. Company insiders that have sold Baxter International stock in the last year include James R Gavin III and John D Forsyth.

Who bought Baxter International stock? Who is buying Baxter International stock?

Baxter International's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Janus Capital Management LLC, State Street Corp, Bogle Investment Management L P DE, Elkfork Partners LLC, New York State Teachers Retirement System, Martingale Asset Management L P and Summit Global Investments.

How do I buy Baxter International stock?

Shares of Baxter International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Baxter International stock cost?

One share of Baxter International stock can currently be purchased for approximately $49.73.

Baxter International (NYSE:BAX) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Earnings History Chart

Earnings by Quarter for Baxter International (NYSE:BAX)

Dividend History Chart

Dividend Payments by Quarter for Baxter International (NYSE:BAX)

Last Updated on 2/21/2017 by Staff